
SUCCESSOR-2 and Mezigdomide in Relapsed/Refractory Multiple Myeloma
Dr. Mansi Shah reviews the SUCCESSOR-2 study, which evaluated mezigdomide plus carfilzomib and dexamethasone compared with carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Episodes in this series

Dr. Mansi Shah reviews the SUCCESSOR-2 study, which evaluated mezigdomide plus carfilzomib and dexamethasone compared with carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. She describes the study design and patient population, highlighting the substantial proportion of patients who were refractory to anti-CD38 monoclonal antibodies and lenalidomide. The discussion covers the improvement in median progression-free survival, overall response rate, depth of response, and duration of response with the mezigdomide-containing regimen. Faculty also review safety findings, particularly the increased incidence of neutropenia, infections, and grade 3 or 4 adverse events. The panel considers the potential relevance of these findings for patients with more heavily pretreated disease and high-risk features. Finally, Dr. Shah compares the populations and treatment settings studied in SUCCESSOR-2 and EXCALIBER-RRMM, emphasizing that the trials evaluated different CELMoDs in different clinical contexts. The results should not be interpreted as establishing a class effect across CELMoDs, as efficacy and safety may vary by agent and patient population.
Related to this article








